Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Sugo

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Nihon Sanka Fujinka Gakkai Zasshi|November 1, 1994
[Mass-screening for ovarian cancer by transvaginal ultrasonography--study on ultrasonographic findings]S Sato, T Sugo, H Maruyama, et al.
European Journal of Biochemistry|February 1, 1993
Role of sugar chains in the in-vitro activity of recombinant human interleukin 5S Kodama, M Tsujimoto, N Tsuruoka, et al.
Biotechnology Progress|October 6, 2001
Purification of docosahexaenoic acid ethyl ester using a silver-ion-immobilized porous hollow-fiber membrane moduleI Ozawa, M Kim, K Saito, et al.
Thrombosis and Haemostasis|December 22, 1999
Structure and function of fibrinogen: insights from dysfibrinogensM Matsuda, T Sugo, N Yoshida, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2006
A classification of the fibrin network structures formed from the hereditary dysfibrinogensT Sugo, H Endo, M Matsuda, et al.
The New England Journal of Medicine|November 10, 1988
A thrombotic state due to an abnormal protein CM Matsuda, T Sugo, Y Sakata, et al.
Annals of the New York Academy of Sciences|July 20, 2001
Mode of perturbation of Asahi fibrin assembly by the extra oligosaccharidesT Sugo, O Sekine, C Nakamikawa, et al.
European Journal of Biochemistry|September 15, 1993
The structure of N-linked oligosaccharides of human pancreatic bile-salt-dependent lipaseT Sugo, E Mas, N Abouakil, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2003
Hypofibrinogenemia caused by a nonsense mutation in the fibrinogen Bbeta chain geneJ Mimuro, A Hamano, T Tanaka, et al.
Blood|June 5, 2001
Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversionS Madoiwa, Y Nakamura, J Mimuro, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Nihon Sanka Fujinka Gakkai Zasshi|November 1, 1994
[Mass-screening for ovarian cancer by transvaginal ultrasonography--study on ultrasonographic findings]S Sato, T Sugo, H Maruyama, et al.
European Journal of Biochemistry|February 1, 1993
Role of sugar chains in the in-vitro activity of recombinant human interleukin 5S Kodama, M Tsujimoto, N Tsuruoka, et al.
Biotechnology Progress|October 6, 2001
Purification of docosahexaenoic acid ethyl ester using a silver-ion-immobilized porous hollow-fiber membrane moduleI Ozawa, M Kim, K Saito, et al.
Thrombosis and Haemostasis|December 22, 1999
Structure and function of fibrinogen: insights from dysfibrinogensM Matsuda, T Sugo, N Yoshida, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2006
A classification of the fibrin network structures formed from the hereditary dysfibrinogensT Sugo, H Endo, M Matsuda, et al.
The New England Journal of Medicine|November 10, 1988
A thrombotic state due to an abnormal protein CM Matsuda, T Sugo, Y Sakata, et al.
Annals of the New York Academy of Sciences|July 20, 2001
Mode of perturbation of Asahi fibrin assembly by the extra oligosaccharidesT Sugo, O Sekine, C Nakamikawa, et al.
European Journal of Biochemistry|September 15, 1993
The structure of N-linked oligosaccharides of human pancreatic bile-salt-dependent lipaseT Sugo, E Mas, N Abouakil, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2003
Hypofibrinogenemia caused by a nonsense mutation in the fibrinogen Bbeta chain geneJ Mimuro, A Hamano, T Tanaka, et al.
Blood|June 5, 2001
Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversionS Madoiwa, Y Nakamura, J Mimuro, et al.
Pageof 8